Spironolactone use and oocyte maturation in patients undergoing controlled ovarian hyperstimulation

Purpose To evaluate the association between spironolactone use and controlled ovarian hyperstimulation (COH) outcomes. Methods Retrospective study, including patients who underwent COH. Oocyte yield and maturation rates were compared by categories of spironolactone use at the start of their cycle. Results 402 patients were included. 83 patients continued spironolactone, 44 patients discontinued spironolactone, and 275 matched control patients were spironolactone-na & iuml;ve. No difference was observed in the number of oocytes retrieved (17 +/- 14 vs. 15 +/- 13, p = 0.4) or mature oocytes vitrified (15 +/- 9.5 vs. 12 +/- 11, p = 0.4) in patients who continued spironolactone use and spironolactone na & iuml;ve patients, respectively. When comparing patients who continued spironolactone use and patients who discontinued spironolactone use, no difference was seen in the number of oocytes retrieved (17 +/- 14 vs. 17.5 +/- 7.8, p = 0.9) or mature oocytes vitrified (15 +/- 9.5 vs. 13.5 +/- 6.5, p = 0.5), respectively. There was no observed relationship between total daily spironolactone dose (< 100mg/day, 100mg/day, 150mg/day and > 200 mg/day) and the total number of mature oocytes vitrified (respectively, 14.0 +/- 13.0, 16.0 +/- 7.8, 14.0 +/- 4.5, 11.0 +/- 7.0 oocytes, p = 0.4). Conclusions This is the first study to evaluate the association between spironolactone and oocyte yield and maturation rates during COH cycles. These findings can assist in counseling patients on the implications of continuing spironolactone during COH cycle.